Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $270.0 million
Deal Type : Series A Financing
Details : The financing will be used to support the advancement of an Industry-leading, comprehensive platform of RNA technologies and a first-in-class portfolio of programmable RNA-based therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : ARCH Venture Partners
Deal Size : $270.0 million
Deal Type : Series A Financing
Lead Product(s) : RNA-Based Vaccine
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Beam Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RNA-based medicines represent fast-growing and disruptive class of therapeutics for a breadth of disease areas. First-generation RNA treatments successfully overcame multiple hurdles, such as the rapid degradation of exogenous RNA, delivery of RNA.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : RNA-Based Vaccine
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Beam Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable